CH848 HIV-1 Envelope Immunogens for bnAb Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV-1 vaccine development has not successfully induced high levels of broadly neutralizing antibodies (bnAbs), which are crucial for protecting against HIV infection, due to challenges in identifying Envs that bind to unmutated common ancestors and early intermediate antibodies of bnAbs, and recreating the antigenic evolution that leads to bnAb induction.
Innovation Solution
The development of immunogenic compositions comprising HIV-1 envelope proteins and nucleic acids, such as gp160, gp120, and gp140, which are used in immunization regimens to prime and boost the immune system, mimicking the 'swarms' of sequentially evolved viruses that occur during bnAb generation in vivo, to trigger appropriate B cell responses and somatic mutation pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional HIV-1 vaccine approaches using single or heterologous Envs are used, then vaccine development is simplified, but the ability to induce broadly neutralizing antibodies is insufficient
Solution Approach 1:
The immunogen is divided into multiple segments representing different stages of viral evolution (transmitted founder virus, early, intermediate, and late Env variants). Each segment targets specific B cell lineage stages, allowing systematic induction of bnAbs through sequential immunization rather than relying on a single complex immunogen
Solution Approach 2:
The vaccine regimen pre-establishes B cell lineages by priming with transmitted founder Env before introducing increasingly diverse viral variants. This preliminary action creates the foundation for subsequent bnAb development by ensuring target B cells are present before antigenic challenge
2Reliability
If immunogens target unmutated common ancestors and early intermediates, then B cell lineage induction is improved, but identification and selection of appropriate Envs becomes more difficult
Solution Approach 1:
The approach uses longitudinal viral sequencing and antibody neutralization assays to monitor B cell lineage responses in real-time. This feedback allows identification of which Env variants are effectively driving bnAb maturation, enabling data-driven selection of immunogen components rather than relying solely on theoretical predictions
Solution Approach 2:
Instead of requiring direct identification and characterization of rare natural bnAb-inducing viruses, the approach creates simplified model systems using genetically engineered Env variants that replicate the essential antigenic features of evolved viral swarms, making them easier to identify and use as immunogens
3Adaptability or versatility
If viral swarm diversity is increased to mimic in vivo evolution, then bnAb breadth is improved, but vaccine composition complexity increases
Solution Approach 1:
Different components of the viral swarm are optimized for different functions: transmitted founder Env for priming and specificity, early variants for lineage expansion, and late diverse variants for breadth induction. Each component has tailored properties suited to its specific role in the immunization sequence
Solution Approach 2:
The vaccine composition is designed to be dynamic rather than static, with the relative proportions and types of viral variants changing across the immunization schedule. Early doses use simpler compositions that progressively evolve into more diverse mixtures, mirroring natural viral evolution while maintaining manufacturability
Data Source
AI summary
In certain aspects the invention provides immunogenic compositions comprising CH848 HIV-1 envelopes and their use in methods to induce immune responses in subjects, e.g., human subjects.